Navigation Links
NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
Date:6/10/2009

ogesX' second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies and NeurogesX is currently evaluating the timing of entering Phase 2 development.

NeurogesX' early stage product pipeline includes pre-clinical compounds, which are prodrugs of acetaminophen and various opioids. The company has evaluated these compounds in vitro and in vivo and is currently seeking development partners for these programs.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to the timing and outcome of regulatory decisions and label approval being sought or that may be obtained with respect to the NDA for Qutenza with the FDA, including the PDUFA date for the NDA; enrollment in and outcomes of clinical trials; the timing of the submission of clinical trial data; acceptance of clinical trial data by the FDA in support of regulatory approval; and NeurogesX' plans and expected timing, with regard to seeking partnerships for its product candidates, including potential commercial partnership for Qutenza in the European Union. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to; positive results in clinical trials may not be sufficient to obtain FDA approval; the FDA may request additional clinical trials or other information prior to granting
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
2. NeurogesX Appoints New Director to the Board
3. NeurogesX to Present at UBS 2007 Global Life Sciences Conference
4. NeurogesX Expands Senior Management Team
5. NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. NeurogesX to Present at Lazard Capital Markets Healthcare Conference
7. NeurogesX, Inc. Announces $25 Million Private Placement
8. NeurogesX Closes $25 Million Private Placement
9. NeurogesX to Present at the 10th Annual BIO CEO & Investor Conference
10. NeurogesX to Present at Roth 2008 OC Growth Stock Conference
11. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... Albany, New York (PRWEB) July 12, 2014 ... market analysis for various reagents used in ... biotechnology is driving the life science reagents ... this study include manufacturers and providers of ... Science Reagents Market Report: http://www.transparencymarketresearch.com/life-sciences-reagents-analytical-reagents.html . ...
(Date:7/11/2014)... , July 11, 2014 ... to announce the appointment of John P. Donoghue ... Biotech   in  Geneva . The ... Campus Biotech in Geneva , has ... recognised neuroscientists. John P. Donoghue , founder of ...
(Date:7/10/2014)... 2014 Product and process impurities ... abundance and are often “lost in the noise,” ... Join presenters Dr. Rowel Tobias, Senior Scientist, Protein ... Head of Quality at Nanotherapeutics, Inc., to lear ... speed detection and quantitation while achieving the required ...
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of Vet-Stem, ... announce the relaunch of his highly informative blog, now named ... “ What are Stem Cells ?” Dr. Harman’s purpose ... in the basics of stem cell therapy so that pet ... of treatment when considering regenerative medicine. , A veterinarian by ...
Breaking Biology Technology:Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 2Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 3John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3
... platform offers multiple diagnostic modalities on a single ... to ... physicians and administrators, SAN DIEGO, March 28 ... of intravascular,ultrasound (IVUS), functional measurement (FM) and Optical Coherence,Tomography (OCT) ...
... /Xinhua-PRNewswire/ -- Tiens Biotech Group (USA),Inc. ("the Company" or ... financial results for the fourth quarter and twelve months ... of 2007 was $13.3 million compared to,$16.6 million for ... the fourth quarter of 2007 was $3.9 million, or ...
... -. Actavis Group, the,international generic pharmaceuticals company, ... approvals from the U.S. Food & Drug ... Distribution,of the products will commence immediately., ... strength, are the generic equivalent of Wellbutrin ...
Cached Biology Technology:Volcano Announces U.S. and European Launch of Rotational IVUS and Integrated FFR 2Volcano Announces U.S. and European Launch of Rotational IVUS and Integrated FFR 3Volcano Announces U.S. and European Launch of Rotational IVUS and Integrated FFR 4Volcano Announces U.S. and European Launch of Rotational IVUS and Integrated FFR 5Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Month Results 2Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Month Results 3Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Month Results 4Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Month Results 5Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Month Results 6Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Month Results 7Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Month Results 8Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Month Results 9Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Month Results 10Actavis Receives Approval of Generic Wellbutrin SR(R) and Zyban(R) Tablets in the U.S. 2
(Date:7/11/2014)... evidence that under the normal circumstances, astrocytes ... maintain neuronal environment, and exhibit therapeutic and ... disease. Previous studies have found that nerve ... chemical induction have reduced viability, which produces ... Xiaodong Yuan, Kailuan General Hospital, Hebei United ...
(Date:7/11/2014)... , July 11, 2014 Research ... "International Biometrics Technology Market - Industry Analysis Size ... to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... and crimes has created a need for high level ... used for personnel authentication such as username and passwords, ...
(Date:7/11/2014)... Janeiro, Brazil- In the brains of all vertebrates, ... allows an electric or chemical signal to be ... synapses, which are the most abundant type of ... formation is crucial for learning, memory, perception and ... synapses critical for brain function. For instance, ...
Breaking Biology News(10 mins):International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2Blame it on the astrocytes 2
... has made new links between 29 regions of the genome ... disease (IBD). The new findings increase the total number of ... to 99. The results point to several biological processes, ... the intestinal wall, which are likely to play an important ...
... With millions of people warding off winter,s chill with ... flags about the potential health effects of the smoke ... American Chemical Society,s (ACS,) journal, Chemical Research in ... the lungs from wood smoke may have several adverse ...
... they seem when it comes to fishsomething scientists at the ... Using modern genetic analysis, combined with traditional examination of morphology, ... three species of blenny in the genus Starksia ... in the scientific journal ZooKeys , Feb. 3. ...
Cached Biology News:Research links 29 genome regions with common form of inflammatory bowel disease 2Research links 29 genome regions with common form of inflammatory bowel disease 3Smithsonian scientists discover 7 new species of fish 2
Mouse Anti-Human Killer Cell Immunoglobulin-like Receptor, Two Domains, Long Cytoplasmic Tail, 2 (KIR2DL2 (KIR2DL3 Monoclonal Antibody Family: Immunoglobulin Sub-Family: not assigned-Immunogl...
pH-dependent fluorescence; Maximum intensity observed in basic solutions....
Mouse anti human pro-Relaxin-2...
Mouse Anti-Human Kallikrein 2 (Hk2)...
Biology Products: